Changes to the Code
S. 1941 · Cure Hepatitis C Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 1395w–102 Prescription drug benefits
4 changes the bill asks for here, 4 carried out
- Carried out:
in paragraph (1)(A), by striking
and (9)
and inserting, (9), and (10)
; - Carried out:
in paragraph (2)(A), by striking
and (9)
and inserting, (9), and (10)
; and - Carried out:
by adding at the end the following new paragraph:
(10) Elimination of cost-sharing for direct acting antivirals for the treatment of hepatitis c.— (A) In general.— For plan years 2027 through 2031, subject to subparagraph (B), with respect to a covered part D drug that is a direct acting antiviral for the treatment of hepatitis …
- Carried out:
in subsection (c), by adding at the end the following new paragraph:
(7) Treatment of cost-sharing for direct acting antivirals for the treatment of hepatitis c.— The coverage is provided in accordance with subsection (b)(10)..
§ 1395w–102(b)Standard prescription drug coverage(1)–(2)
Start of § 1395w–102 to (a)(5) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b) | (b) Standard prescription drug coverage | (b) Standard prescription drug coverage | ||
| For purposes of this part and part C, the term “standard prescription drug coverage” means coverage of covered part D drugs that meets the following requirements: | For purposes of this part and part C, the term “standard prescription drug coverage” means coverage of covered part D drugs that meets the following requirements: | |||
| (1) | (1) Deductible | (1) Deductible | ||
| (1)(A) | (A) In general | (A) In general | ||
| Subject to paragraphs (8) | Subject to paragraphs (8) [inserted: ,] (9), [inserted: and (10), ]the coverage has an annual deductible— | |||
| (1)(A)(i) | (i) | (i) | ||
| for 2006, that is equal to $250; or | for 2006, that is equal to $250; or | |||
| (1)(A)(ii) | (ii) | (ii) | ||
| for a subsequent year, that is equal to the amount specified under this paragraph for the previous year increased by the percentage specified in paragraph (6) for the year involved. | for a subsequent year, that is equal to the amount specified under this paragraph for the previous year increased by the percentage specified in paragraph (6) for the year involved. | |||
| (1)(B) | (B) Rounding | (B) Rounding | ||
| Any amount determined under subparagraph (A)(ii) that is not a multiple of $5 shall be rounded to the nearest multiple of $5. | Any amount determined under subparagraph (A)(ii) that is not a multiple of $5 shall be rounded to the nearest multiple of $5. | |||
| (2) | (2) Benefit structure | (2) Benefit structure | ||
| (2)(A) | (A) 25 percent coinsurance | (A) 25 percent coinsurance | ||
| Subject to subparagraphs (C), (D), and (E) and paragraphs (8) | Subject to subparagraphs (C), (D), and (E) and paragraphs (8) [inserted: ,] (9), [inserted: and (10), ]the coverage has coinsurance (for costs above the annual deductible specified in paragraph (1) and up to the initial coverage limit under paragraph (3) for a year preceding 2025 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2025 and each subsequent year) that is— | |||
| (2)(A)(i) | (i) | (i) | ||
| equal to 25 percent; or | equal to 25 percent; or | |||
| (2)(A)(ii) | (ii) | (ii) | ||
| actuarially equivalent (using processes and methods established under section 1395w–111(c) of this title) to an average expected payment of 25 percent of such costs. | actuarially equivalent (using processes and methods established under section 1395w–111(c) of this title) to an average expected payment of 25 percent of such costs. |
§ 1395w–102(b)–(c)
(b)(2)(B)–(9)(D) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(9)(D)(ii)(III) | (III) | (III) | ||
| an amount equal to 25 percent of the negotiated price of the covered insulin product under the prescription drug plan or MA–PD plan. | an amount equal to 25 percent of the negotiated price of the covered insulin product under the prescription drug plan or MA–PD plan. | |||
| (b)(9)(E) | (E) Special rule for first 3 months of 2023 | (E) Special rule for first 3 months of 2023 | ||
| With respect to a month’s supply of a covered insulin product dispensed during the period beginning on January 1, 2023, and ending on March 31, 2023, a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan shall reimburse an enrollee within 30 days for any cost-sharing paid by such enrollee that exceeds the cost-sharing applied by the prescription drug plan or MA–PD plan under subparagraph (B)(i) at the point-of-sale for such month’s supply. | With respect to a month’s supply of a covered insulin product dispensed during the period beginning on January 1, 2023, and ending on March 31, 2023, a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan shall reimburse an enrollee within 30 days for any cost-sharing paid by such enrollee that exceeds the cost-sharing applied by the prescription drug plan or MA–PD plan under subparagraph (B)(i) at the point-of-sale for such month’s supply. | |||
| (b)(10) | (10) [inserted: Elimination of cost-sharing for direct acting antivirals for the treatment of hepatitis c.—] | |||
| (b)(10)(A) | (A) [inserted: In general.—] | |||
| [inserted: For plan years 2027 through 2031, subject to subparagraph (B), with respect to a covered part D drug that is a direct acting antiviral for the treatment of hepatitis C—] | ||||
| (b)(10)(A)(i) | (i) [inserted: ] | |||
| [inserted: the deductible under paragraph (1) shall not apply; and] | ||||
| (b)(10)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: there shall be no coinsurance or other cost-sharing under this part with respect to such drug.] | ||||
| (b)(10)(B) | (B) [inserted: Authority to delay implementation.—] | |||
| [inserted: If the Secretary determines that it is not feasible to implement subparagraph (A) for plan year 2027, subparagraph (A) shall be applied by substituting “2028” for “2027”.] | ||||
| (c) | (c) Alternative prescription drug coverage requirements | (c) Alternative prescription drug coverage requirements | ||
| A prescription drug plan or an MA–PD plan may provide a different prescription drug benefit design from standard prescription drug coverage so long as the Secretary determines (consistent with section 1395w–111(c) of this title) that the following requirements are met and the plan applies for, and receives, the approval of the Secretary for such benefit design: | A prescription drug plan or an MA–PD plan may provide a different prescription drug benefit design from standard prescription drug coverage so long as the Secretary determines (consistent with section 1395w–111(c) of this title) that the following requirements are met and the plan applies for, and receives, the approval of the Secretary for such benefit design: | |||
| (c)(1) | (1) Assuring at least actuarially equivalent coverage | (1) Assuring at least actuarially equivalent coverage | ||
§ 1395w–102(c)–(d)
(c)(1)(A)–(4) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (c)(5) | (5) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices | (5) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices | ||
| The coverage is in accordance with subsection (b)(8). | The coverage is in accordance with subsection (b)(8). | |||
| (c)(6) | (6) Treatment of cost-sharing for covered insulin products | (6) Treatment of cost-sharing for covered insulin products | ||
| The coverage is provided in accordance with subsection (b)(9). | The coverage is provided in accordance with subsection (b)(9). | |||
| (c)(7) | (7) [inserted: Treatment of cost-sharing for direct acting antivirals for the treatment of hepatitis c.—] | |||
| [inserted: The coverage is provided in accordance with subsection (b)(10).] | ||||
| (d) | (d) Access to negotiated prices | (d) Access to negotiated prices | ||
| (d)(1) | (1) Access | (1) Access | ||
| (d)(1)(A) | (A) In general | (A) In general | ||
| Under qualified prescription drug coverage offered by a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan, the sponsor or organization shall provide enrollees with access to negotiated prices used for payment for covered part D drugs, regardless of the fact that no benefits may be payable under the coverage with respect to such drugs because of the application of a deductible or other cost-sharing or, for a year preceding 2025, an initial coverage limit (described in subsection (b)(3)). | Under qualified prescription drug coverage offered by a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan, the sponsor or organization shall provide enrollees with access to negotiated prices used for payment for covered part D drugs, regardless of the fact that no benefits may be payable under the coverage with respect to such drugs because of the application of a deductible or other cost-sharing or, for a year preceding 2025, an initial coverage limit (described in subsection (b)(3)). | |||
Rest of § 1395w–102 unchanged
42 U.S.C. § 1395w–114 Premium and cost-sharing subsidies for low-income individuals
2 changes the bill asks for here, 2 carried out
- Carried out:
in paragraph (1)(D), in each of clauses (ii) and (iii), by striking
paragraph (6)
and insertingparagraphs (6) and (7)
; and - Carried out:
by adding at the end the following new paragraph:
(7) No application of cost-sharing or deductible for direct acting antivirals for the treatment of hepatitis c.— (A) In general.— For plan years 2027 through 2031, subject to subparagraph (B), with respect to a covered part D drug that is a direct acting antiviral for the …
§ 1395w–114(a)(1)(D)Reduction in cost-sharing below out-of-pocket threshold(i)–(ii)
Start of § 1395w–114 to (a)(1)(D) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (i) | (i) Institutionalized individuals | (i) Institutionalized individuals | ||
| In the case of an individual who is a full-benefit dual eligible individual and who is an institutionalized individual or couple (as defined in section 1396a(q)(1)(B) of this title) or, effective on a date specified by the Secretary (but in no case earlier than January 1, 2012), who would be such an institutionalized individual or couple, if the full-benefit dual eligible individual were not receiving services under a home and community-based waiver authorized for a State under section 1315 of this title or subsection (c) or (d) of section 1396n of this title or under a State plan amendment under subsection (i) of such section or services provided through enrollment in a medicaid managed care organization with a contract under section 1396b(m) of this title or under section 1396u–2 of this title, the elimination of any beneficiary coinsurance described in section 1395w–102(b)(2) of this title (for all amounts through the total amount of expenditures at which benefits are available under section 1395w–102(b)(4) of this title). | In the case of an individual who is a full-benefit dual eligible individual and who is an institutionalized individual or couple (as defined in section 1396a(q)(1)(B) of this title) or, effective on a date specified by the Secretary (but in no case earlier than January 1, 2012), who would be such an institutionalized individual or couple, if the full-benefit dual eligible individual were not receiving services under a home and community-based waiver authorized for a State under section 1315 of this title or subsection (c) or (d) of section 1396n of this title or under a State plan amendment under subsection (i) of such section or services provided through enrollment in a medicaid managed care organization with a contract under section 1396b(m) of this title or under section 1396u–2 of this title, the elimination of any beneficiary coinsurance described in section 1395w–102(b)(2) of this title (for all amounts through the total amount of expenditures at which benefits are available under section 1395w–102(b)(4) of this title). | |||
| (ii) | (ii) Lowest income dual eligible individuals | (ii) Lowest income dual eligible individuals | ||
| Subject to | Subject to [inserted: paragraphs] (6)[inserted: and (7)], in the case of an individual not described in clause (i) who is a full-benefit dual eligible individual and whose income does not exceed 100 percent of the poverty line applicable to a family of the size involved, the substitution for the beneficiary coinsurance described in section 1395w–102(b)(2) of this title (for all amounts through the total amount of expenditures at which benefits are available under section 1395w–102(b)(4) of this title) of a copayment amount that does not exceed— | |||
| (ii)(I) | (I) | (I) | ||
| for a plan year before 2028— | for a plan year before 2028— | |||
| (ii)(I)(aa) | (aa) | (aa) | ||
| for a generic drug or a preferred drug that is a multiple source drug (as defined in section 1396r–8(k)(7)(A)(i) of this title), $1 or, if less, the copayment amount applicable to an individual under clause (iii); and | for a generic drug or a preferred drug that is a multiple source drug (as defined in section 1396r–8(k)(7)(A)(i) of this title), $1 or, if less, the copayment amount applicable to an individual under clause (iii); and |
§ 1395w–114(a)Income-related subsidies for certain individuals(1)–(2)
(a)(1)(D)(ii)(I)(bb)–(II)(bb) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (1)(D)(ii)(II)(cc) | (cc) | (cc) | ||
| for a drug not described in either item (aa) or (bb), the dollar amount applied under this clause for such a drug for the preceding plan year, increased in the manner specified in item (bb), or, if less, the copayment amount applicable to an individual under clause (iii). | for a drug not described in either item (aa) or (bb), the dollar amount applied under this clause for such a drug for the preceding plan year, increased in the manner specified in item (bb), or, if less, the copayment amount applicable to an individual under clause (iii). | |||
| (1)(D) | Any amount established under item (bb) or (cc) of subclause (II), that is based on an increase of $1 or $3, that is not a multiple of 5 cents or 10 cents, respectively, shall be rounded to the nearest multiple of 5 cents or 10 cents, respectively. | Any amount established under item (bb) or (cc) of subclause (II), that is based on an increase of $1 or $3, that is not a multiple of 5 cents or 10 cents, respectively, shall be rounded to the nearest multiple of 5 cents or 10 cents, respectively. | ||
| (1)(D)(iii) | (iii) Other individuals | (iii) Other individuals | ||
| Subject to | Subject to [inserted: paragraphs] (6)[inserted: and (7)], in the case of an individual not described in clause (i) or (ii), the substitution for the beneficiary coinsurance described in section 1395w–102(b)(2) of this title (for all amounts through the total amount of expenditures at which benefits are available under section 1395w–102(b)(4) of this title) of a copayment amount that does not exceed the copayment amount specified under section 1395w–102(b)(4)(A)(i)(I)(aa) of this title for the drug and year involved. For plan year 2023 and subsequent plan years, the copayment amount applicable under the preceding sentence to a month’s supply of a covered insulin product (as defined in section 1395w–102(b)(9)(C) of this title) dispensed to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled. | |||
| (1)(E) | (E) Elimination of cost-sharing above annual out-of-pocket threshold | (E) Elimination of cost-sharing above annual out-of-pocket threshold | ||
| For a year preceding 2024, the elimination of any cost-sharing imposed under section 1395w–102(b)(4)(A) of this title or under section 1395w–102(b)(9) of this title in the case of a covered insulin product (as defined in subparagraph (C) of such section). | For a year preceding 2024, the elimination of any cost-sharing imposed under section 1395w–102(b)(4)(A) of this title or under section 1395w–102(b)(9) of this title in the case of a covered insulin product (as defined in subparagraph (C) of such section). | |||
| (2) | (2) Other low-income individuals | (2) Other low-income individuals | ||
| With respect to a plan year beginning before January 1, 2024, in the case of a subsidy eligible individual who is not described in paragraph (1), the individual is entitled under this section to the following: | With respect to a plan year beginning before January 1, 2024, in the case of a subsidy eligible individual who is not described in paragraph (1), the individual is entitled under this section to the following: |
§ 1395w–114(a)–(b)
(a)(2)(A)–(6) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (a)(6)(A) | (A) | (A) | ||
| the deductible under section 1395w–102(b)(1) of this title shall not apply; and | the deductible under section 1395w–102(b)(1) of this title shall not apply; and | |||
| (a)(6)(B) | (B) | (B) | ||
| there shall be no cost-sharing under this section with respect to such vaccine. | there shall be no cost-sharing under this section with respect to such vaccine. | |||
| (a)(7) | (7) [inserted: No application of cost-sharing or deductible for direct acting antivirals for the treatment of hepatitis c.—] | |||
| (a)(7)(A) | (A) [inserted: In general.—] | |||
| [inserted: For plan years 2027 through 2031, subject to subparagraph (B), with respect to a covered part D drug that is a direct acting antiviral for the treatment of hepatitis C—] | ||||
| (a)(7)(A)(i) | (i) [inserted: ] | |||
| [inserted: the deductible under section 1860D–2(b)(1) shall not apply; and] | ||||
| (a)(7)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: there shall be no cost-sharing under this section with respect to such drug.] | ||||
| (a)(7)(B) | (B) [inserted: Authority to delay implementation.—] | |||
| [inserted: If the Secretary determines that it is not feasible to implement subparagraph (A) for plan year 2027, subparagraph (A) shall be applied by substituting “2028” for “2027”.] | ||||
| (b) | (b) Premium subsidy amount | (b) Premium subsidy amount | ||
| (b)(1) | (1) In general | (1) In general | ||
| The premium subsidy amount described in this subsection for a subsidy eligible individual residing in a PDP region and enrolled in a prescription drug plan or MA–PD plan is the low-income benchmark premium amount (as defined in paragraph (2)) for the PDP region in which the individual resides or, if greater, the amount specified in paragraph (3). | The premium subsidy amount described in this subsection for a subsidy eligible individual residing in a PDP region and enrolled in a prescription drug plan or MA–PD plan is the low-income benchmark premium amount (as defined in paragraph (2)) for the PDP region in which the individual resides or, if greater, the amount specified in paragraph (3). | |||
Rest of § 1395w–114 unchanged
42 U.S.C. § 1396r–8 Payment for covered outpatient drugs
7 changes the bill asks for here, 6 carried out
- Carried out:
in subclause (V), by striking
; and
and inserting a semicolon;
- Carried out:
in subclause (VI), by striking the period at the end and inserting
; and
; and - Carried out:
by adding at the end the following new subclause:
(VII) any prices charged under the subscription program for hepatitis C treatments established under section 4(b) of the Cure Hepatitis C Act of 2025.; and
- Not carried out:
in subclause (IV), by inserting a semicolon at the end;
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: inserting a semicolon at the end; - Carried out:
in subclause (VII), by striking
; and
and inserting a semicolon;
- Carried out:
in subclause (VIII), by striking the period at the end and inserting
; and
; and - Carried out:
by adding at the end the following new subclause:
(IX) any prices charged under the subscription program for hepatitis C treatments established under section 4(b) of the Cure Hepatitis C Act of 2025..
§ 1396r–8(c)(1)(C)“Best price” defined(i)–(ii)
Start of § 1396r–8 to (c)(1)(C)(i)(III) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (i)(IV) | (IV) | (IV) | ||
| any depot prices and single award contract prices, as defined by the Secretary, of any agency of the Federal Government; | any depot prices and single award contract prices, as defined by the Secretary, of any agency of the Federal Government; | |||
| (i)(V) | (V) | (V) | ||
| the prices negotiated from drug manufacturers for covered discount card drugs under an endorsed discount card program under section 1395w–141 of this title; | the prices negotiated from drug manufacturers for covered discount card drugs under an endorsed discount card program under section 1395w–141 of this title; | |||
| (i)(VI) | (VI) | (VI) | ||
| subject to clause (ii)(V), any prices charged which are negotiated by a prescription drug plan under part D of subchapter XVIII, by an MA–PD plan under part C of such subchapter with respect to covered part D drugs or by a qualified retiree prescription drug plan (as defined in section 1395w–132(a)(2) of this title) with respect to such drugs on behalf of individuals entitled to benefits under part A or enrolled under part B of such subchapter, or any discounts provided by manufacturers under the Medicare coverage gap discount program under section 1395w–114a of this title or under the manufacturer discount program under section 1395w–114c of this title | subject to clause (ii)(V), any prices charged which are negotiated by a prescription drug plan under part D of subchapter XVIII, by an MA–PD plan under part C of such subchapter with respect to covered part D drugs or by a qualified retiree prescription drug plan (as defined in section 1395w–132(a)(2) of this title) with respect to such drugs on behalf of individuals entitled to benefits under part A or enrolled under part B of such subchapter, or any discounts provided by manufacturers under the Medicare coverage gap discount program under section 1395w–114a of this title or under the manufacturer discount program under section 1395w–114c of this title[inserted: ; and] | |||
| (i)(VII) | (VII) [inserted: ] | |||
| [inserted: any prices charged under the subscription program for hepatitis C treatments established under section 4(b) of the Cure Hepatitis C Act of 2025.] | ||||
| (ii) | (ii) Special rules | (ii) Special rules | ||
| The term “best price”— | The term “best price”— | |||
| (ii)(I) | (I) | (I) | ||
| shall be inclusive of cash discounts, free goods that are contingent on any purchase requirement, volume discounts, and rebates (other than rebates under this section, section 1395w–3a(i) of this title, or section 1395w–114b of this title); | shall be inclusive of cash discounts, free goods that are contingent on any purchase requirement, volume discounts, and rebates (other than rebates under this section, section 1395w–3a(i) of this title, or section 1395w–114b of this title); | |||
§ 1396r–8(k)(1)Average manufacturer price(B)–(C)
(c)(1)(C)(ii)(II)–(k)(1)(B)(i)(V) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (B)(i)(VI) | (VI) | (VI) | ||
| any reduction in price paid during the rebate period to the manufacturer for a drug by reason of application of part E of subchapter XI; | any reduction in price paid during the rebate period to the manufacturer for a drug by reason of application of part E of subchapter XI; | |||
| (B)(i)(VII) | (VII) | (VII) | ||
| rebates paid by manufacturers under section 1395w–3a(i) of this title; | rebates paid by manufacturers under section 1395w–3a(i) of this title; | |||
| (B)(i)(VIII) | (VIII) | (VIII) | ||
| rebates paid by manufacturers under section 1395w–114b of this title | rebates paid by manufacturers under section 1395w–114b of this title[inserted: ; and] | |||
| (B)(i)(IX) | (IX) [inserted: ] | |||
| [inserted: any prices charged under the subscription program for hepatitis C treatments established under section 4(b) of the Cure Hepatitis C Act of 2025.] | ||||
| (B)(ii) | (ii) Inclusion of other discounts and payments | (ii) Inclusion of other discounts and payments | ||
| Notwithstanding clause (i), any other discounts, rebates, payments, or other financial transactions that are received by, paid by, or passed through to, retail community pharmacies shall be included in the average manufacturer price for a covered outpatient drug. | Notwithstanding clause (i), any other discounts, rebates, payments, or other financial transactions that are received by, paid by, or passed through to, retail community pharmacies shall be included in the average manufacturer price for a covered outpatient drug. | |||
| (C) | (C) Exclusion of section 505(c) drugs | (C) Exclusion of section 505(c) drugs | ||
| In the case of a manufacturer that approves, allows, or otherwise permits any drug of the manufacturer to be sold under the manufacturer’s new drug application approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c)], such term shall be exclusive of the average price paid for such drug by wholesalers for drugs distributed to retail community pharmacies. | In the case of a manufacturer that approves, allows, or otherwise permits any drug of the manufacturer to be sold under the manufacturer’s new drug application approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c)], such term shall be exclusive of the average price paid for such drug by wholesalers for drugs distributed to retail community pharmacies. | |||
Rest of § 1396r–8 unchanged